Literature DB >> 16143986

Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger".

Alexandra J Corbett1, Irina Caminschi, Brent S McKenzie, Jamie L Brady, Mark D Wright, Patricia L Mottram, P Mark Hogarth, Anthony N Hodder, Yifan Zhan, David M Tarlinton, Ken Shortman, Andrew M Lew.   

Abstract

Targeting antigen to dendritic cells (DC) in vivo might be an effective method of modulating immune responses. Given the functional specializations among DC subsets, we investigated how targeting different receptors on different DC subsets may influence antibody (Ab) production. We show here that targeting FIRE (F4/80-like receptor) or CIRE (C-type lectin receptor), two molecules expressed on the surface of immature CD8- DC in the mouse, increases Ab production 100-1000-fold over a non-targeted control. This response was equivalent to that achieved with CpG adjuvant. In contrast, targeting CD205, which is primarily expressed on CD8+ DC, did not elicit an Ab response unless an adjuvant was added. Strong Ab responses in FcRgamma-/- mice, and with the use of F(ab')2 fragments, confirmed that FIRE and CIRE targeting was due to specific rather than FcR or complement binding. Our findings may reflect differences in the ability of CD8+ and CD8- DC subsets to stimulate immune responses in vivo. Although the consensus view is that Ag presentation on DC in their steady state leads to tolerance, the Ab enhancement from FIRE and CIRE targeting in the apparent absence of any "danger" or inflammatory signal would suggest that targeting certain DC molecules can supplant the need for external adjuvants for eliciting immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143986     DOI: 10.1002/eji.200526100

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.

Authors:  Petra Schnorrer; Georg M N Behrens; Nicholas S Wilson; Joanne L Pooley; Christopher M Smith; Dima El-Sukkari; Gayle Davey; Fiona Kupresanin; Ming Li; Eugene Maraskovsky; Gabrielle T Belz; Francis R Carbone; Ken Shortman; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

3.  Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Authors:  Louise J Young; Nicholas S Wilson; Petra Schnorrer; Adele Mount; Rachel J Lundie; Nicole L La Gruta; Brendan S Crabb; Gabrielle T Belz; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

Review 4.  Improving vaccines by targeting antigens to dendritic cells.

Authors:  Ken Shortman; Mireille H Lahoud; Irina Caminschi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

5.  STALing B cell responses with CD22.

Authors:  Craig P Chappell; Edward A Clark
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

Review 6.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

Review 7.  Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.

Authors:  Jardin Leleux; Alexandra Atalis; Krishnendu Roy
Journal:  J Control Release       Date:  2015-10-20       Impact factor: 9.776

8.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

9.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Authors:  Irina Caminschi; Anna I Proietto; Fatma Ahmet; Susie Kitsoulis; Joo Shin Teh; Jennifer C Y Lo; Alexandra Rizzitelli; Li Wu; David Vremec; Serani L H van Dommelen; Ian K Campbell; Eugene Maraskovsky; Hal Braley; Gayle M Davey; Patricia Mottram; Nicholas van de Velde; Kent Jensen; Andrew M Lew; Mark D Wright; William R Heath; Ken Shortman; Mireille H Lahoud
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

10.  Display of Native Antigen on cDC1 That Have Spatial Access to Both T and B Cells Underlies Efficient Humoral Vaccination.

Authors:  Yu Kato; Thiago M Steiner; Hae-Young Park; Rohan O Hitchcock; Ali Zaid; Jyh Liang Hor; Sapna Devi; Gayle M Davey; David Vremec; Kirsteen M Tullett; Peck S Tan; Fatma Ahmet; Scott N Mueller; Sylvie Alonso; David M Tarlinton; Hidde L Ploegh; Tsuneyasu Kaisho; Lynette Beattie; Jonathan H Manton; Daniel Fernandez-Ruiz; Ken Shortman; Mireille H Lahoud; William R Heath; Irina Caminschi
Journal:  J Immunol       Date:  2020-08-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.